MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.
Molecular and genetic testing has become a game-changer in brain tumor care - shaping diagnosis, guiding treatments and opening doors to new therapies. Once available to a handful of patients, these ...
A 10-year study shows that a multipronged approach using whole exome sequencing can improve diagnostic yield in patients with ...
Current Practices, Perceived Barriers, and Promising Implementation Strategies for Improving Quality of Smoking Cessation Support in Accredited Cancer Programs of the American College of Surgeons This ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data ...
(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral blood ...
In a recent blog, I discussed the change in nomenclature for the conditions formerly known as Neurofibromatosis type 2 (NF2) and schwannomatosis. This change was based on the results of an ...
Global Molecular Infectious Disease Testing Market OverviewThe global molecular infectious disease testing market is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results